Murat Tunaboylu

Murat Tunaboylu is a Turkish engineer and entrepreneur who grew up in Turkey, where he completed a Bachelor's degree in Electrical Engineering at Yildiz Technical University and a Master's degree in Computer Engineering at Bahçeşehir University. His educational background bridged hardware and software, giving him a multidisciplinary foundation that would later prove central to his approach to drug discovery.

Tunaboylu began his career in software engineering, including a period at Susquehanna International Group (SIG), before moving into the life sciences technology space. He worked as a software manager at a robotics company and subsequently at Thermo Fisher Scientific, where he automated DNA synthesis workflows as a Synthetic Biology MES Senior Developer. This immersion in biological laboratory infrastructure gave him a direct understanding of the inefficiencies at the heart of experimental drug development.

In 2017, Tunaboylu co-founded Antiverse in Cardiff with Ben Holland, with a mission to apply machine learning and in-house laboratory expertise to antibody discovery for the most challenging drug targets in medicine — GPCRs and ion channels, which are implicated in over 200 diseases but have fewer than ten FDA-approved antibody treatments. As CEO, he has built the company's lab-in-the-loop platform, which designs antibody candidates computationally and tests them in native cell models, reducing discovery timelines from years to approximately four months.

Antiverse raised $9.3 million (£7 million) in a Series A in March 2026, led by Soulmates Ventures. The company has established collaboration agreements with multiple top-20 global pharmaceutical companies and holds a research agreement with the Cystic Fibrosis Foundation. Total funding exceeds $20 million since founding.